methadone hydrochloride tablets usp
specgx llc - methadone (methadone hydrochloride) - tablets - 5mg
methadone hydrochloride tablets usp
specgx llc - methadone (methadone hydrochloride) - tablets - 10mg
talwin tablet
sanofi-aventis canada inc - pentazocine (pentazocine hydrochloride) - tablet - 50mg - pentazocine (pentazocine hydrochloride) 50mg - opiate partial agonists
methadose dispersible tablets usp
specgx llc - methadone (methadone hydrochloride) - tablets for oral suspension - 40mg
ixprim 37.5/325 milligram tablets effervescent
grünenthal ltd - paracetamol, tramadol hydrochloride - tablets effervescent - 37.5/325 milligram - opiods in combination with non-opiod analgesics
venlafaxine teva 37.5 milligram tablets
teva pharma b.v. - venlafaxine hydrochloride - tablets - 37.5 milligram - other antidepressants
venlafaxine teva 75 milligram tablets
teva pharma b.v. - venlafaxine hydrochloride - tablets - 75 milligram - other antidepressants
desvenlafaxine gh xr desvenlafaxine (as benzoate) 100 mg extended release tablets blister pack
lupin australia pty limited - desvenlafaxine benzoate, quantity: 146.32 mg (equivalent: desvenlafaxine, qty 100 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; sunset yellow fcf aluminium lake; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.
desvenlafaxine gh xr desvenlafaxine (as benzoate) 50 mg extended release tablets blister pack
lupin australia pty limited - desvenlafaxine benzoate, quantity: 73.16 mg (equivalent: desvenlafaxine, qty 50 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.
desvenlafaxine sandoz desvenlafaxine 50mg modified release tablets blister
medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; citric acid monohydrate; magnesium stearate; povidone; purified talc; alginic acid; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.